CAS 1210608-87-9 Lapatinib-[13C,d7] - Isotope / BOC Sciences

General Information
Catalog: BLP-011601
CAS: 1210608-87-9
Molecular Formula: C28[13C]H19D7ClFN4O4S
Molecular Weight: 589.09

General Information

Catalog: BLP-011601

CAS: 1210608-87-9

Molecular Formula: C28[13C]H19D7ClFN4O4S

Molecular Weight: 589.09

Chemical Structure

Catalog Number	Size	Price	Stock	Quantity
BLP-011601	1 mg	$998	In stock

Catalog Number

Size

Price

Stock

Quantity

BLP-011601

1 mg

$998

In stock

Description	Lapatinib-[13C,d7] is the labelled analogue of Lapatinib, a reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. It can be used for the treatment of breast cancer and other solid tumours.
Synonyms	Lapatinib-13C,D7; Lapatinib Ditosylate-13C,d7; Tykerb-13C,d7; GW 572016-13C,d7; Tyverb-13C,d7; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(13C,D3)methanesulfonyl(D4)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
IUPAC Name	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[1,1,2,2-tetradeuterio-2-(trideuterio(1-13C)methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
Related CAS	231277-92-2 (unlabelled)
Canonical SMILES	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChI	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)/i1+1D3,11D2,12D2
InChI Key	BCFGMOOMADDAQU-FFSONIBRSA-N
Purity	95% by HPLC; 98% atom 13C; 98% atom D
Solubility	Soluble in DMSO (Slightly), Methanol (Slightly, Sonicated)
Appearance	Pale Yellow Solid
Storage	Store at -20°C

Lapatinib-[13C,d7], an isotopically labeled variant of Lapatinib, finds predominant application in research contexts for investigating its pharmacokinetics and metabolic pathways. Here are the key applications of Lapatinib-[13C,d7]:

Pharmacokinetic Studies: Employing Lapatinib-[13C,d7] in pharmacokinetic investigations affords researchers insights into the absorption, distribution, metabolism, and excretion of Lapatinib within the body. By utilizing this labeled compound, researchers can meticulously quantify the concentration of Lapatinib across various tissues using mass spectrometry techniques. This precise measurement aids in comprehending the bioavailability of the drug and optimizing dosing schedules.

Metabolite Identification: Within drug metabolism assessments, Lapatinib-[13C,d7] plays a pivotal role in identifying and characterizing the metabolic routes of Lapatinib. The isotopic labeling facilitates the accurate discrimination between parent compounds and metabolites during analytical analyses. This data is critical for assessing the safety and efficacy of the drug by pinpointing potentially toxic metabolites that may arise.

Drug Interaction Studies: In investigations into drug-drug interactions, Lapatinib-[13C,d7] is a valuable tool for evaluating how concomitant medications impact the pharmacokinetics of Lapatinib. Monitoring the labeled compound allows researchers to discern the influence of co-administered drugs on Lapatinib's behavior in the body. These studies contribute to shaping guidelines for the judicious and effective use of multiple medications.

Quantitative Mass Spectrometry: Within the realm of quantitative mass spectrometry, Lapatinib-[13C,d7] functions as an internal standard for the precise quantitation of Lapatinib within biological samples. The isotopic label ensures accurate differentiation of Lapatinib from endogenous compounds and other pharmaceutical substances. This methodology is indispensable for establishing robust bioanalytical procedures essential for clinical trials and bioequivalence assessments.